Ophthalmic viscoelastic device and kit for use in eye surgery
The degradable ophthalmic viscoelastic device with reversibly coupled polymer chains addresses the challenge of complete removal and intraocular pressure by adjusting viscosity post-surgery, ensuring safer and faster handling and reduced surgical time.
Patent Information
- Application Number
- PCT/EP2024/067691
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-27
- Filing Date
- 2024-06-24
- Publication Date
- 2025-01-02
AI Technical Summary
Current ophthalmic viscoelastic devices (OVDs) are challenging to remove completely after eye surgery, leading to potential increased intraocular pressure and risk of glaucoma due to residual polymer chains blocking the trabecular meshwork, especially with dispersive OVDs, and high-viscosity cohesive OVDs are difficult to manage and remove efficiently.
A degradable ophthalmic viscoelastic device with reversibly coupled polymer chains, allowing for adjustable rheological properties via a binding additive that can be cleaved post-surgery, enabling safer and faster handling by converting into shorter-chain polymers for easy biodegradation or higher-viscosity forms for easier removal.
Enables precise adaptation of rheological properties during surgery, facilitating quicker and complete removal of OVDs without increasing intraocular pressure, reducing surgical time, and minimizing post-operative risks.
Smart Images

Figure EP2024067691_02012025_PF_FP_ABST
Abstract
Description
[0001] Ophthalmic viscoelastic device and kit for use in eye surgery
[0002] Technical area
[0003] The invention relates to a degradable ophthalmic viscoelastic device and a kit for use in eye surgery with such an ophthalmic viscoelastic device.
[0004] State of the art
[0005] Cataracts are a common condition, especially among older people, in which the lens of the eye gradually becomes opaque. This clouding of the natural lens leads to a loss of visual acuity. Cataract surgery is required to restore vision. The standard method for removing the cloudy lens nucleus to create a capsular bag for the insertion of an artificial intraocular lens (IOL) is called phacoemulsification, using a device that generates ultrasonic vibrations.
[0006] Immediately before phacoemulsification, the anterior chamber is usually filled with an ophthalmic viscoelastic device (OVD). The viscoelastic OVD is used as a surgical aid to protect intraocular tissue (e.g., the corneal endothelium during phacoemulsification), as a space maintainer (e.g., to maintain the anterior chamber), and to facilitate intraocular procedures, such as performing a controlled capsulorhexis. Such OVDs are also used in other eye surgeries, such as corneal transplants or glaucoma surgery.
[0007] OVDs are typically water-based solutions containing viscoelastic polymers such as hyaluronic acid (HA), chondroitin sulfate (CS), hydroxypropyl methylcellulose (HPMC), or mixtures thereof. The viscoelastic composition can vary depending on the molecular weight of the polysaccharide dissolved in the solution, the concentration of the polysaccharide, and the viscosity of the solution. The rheological properties are highly dependent on the concentration and molecular mass of the polymers.
[0008] Generally, two types of OVDs are distinguished. Highly viscous, cohesive OVDs hold the space and build pressure. They are used, for example, to dilate the pupil before the anterior capsular bag of the lens is opened (capsulorhexis). Cohesive OVDs are made of high-molecular-weight polymers.
[0009] In contrast, less viscous, dispersive OVDs envelop and protect the tissue. One of their most important applications is the creation of an adherent polymer barrier with a layer thickness of approximately 100 μm to approximately 1 mm between the corneal endothelium and the anterior chamber of the eye. Disperse OVDs contain polymer chains with lower molecular weights compared to cohesive OVDs.
[0010] While a longer-chain, cohesive OVD can be washed out by flushing the anterior chamber with a suitable irrigation solution, shorter-chain, dispersive OVDs are significantly more difficult to remove or aspirate after surgery. At the end of cataract surgery, the surgeon is often confronted with a layer of OVD covering the cornea and extending to the corner of the eye. An additional challenge is that the dispersive OVD material is usually located directly on the endothelium, where it is generally difficult to aspirate, and in the corner of the eye, where it is also difficult to detect.
[0011] Residual OVD remaining in the eye after surgery can be gradually washed out by the aqueous humor and transported away via the trabecular meshwork. However, polymer chains that are too long can partially clog the trabecular meshwork and delay or completely prevent its removal. This can then lead to increased intraocular pressure (IOP) after surgery. However, increased intraocular pressure poses a risk to the patient, as it can lead to glaucoma.
[0012] Therefore, highly viscous (cohesive) OVDs for the manipulation and removal of tissue as well as low-viscosity (dispersive) OVDs, which are particularly suitable for cell protection, are desirable, whereby both types of OVDs can be removed from the eye as easily and completely as possible after use.
[0013] Description of the invention
[0014] The object of the present invention is to provide an ophthalmic viscoelastic device for use in eye surgery, which can be designed either as a cohesive OVD or as a dispersive OVD and enables safer and faster handling in both cases. A further object of the invention is to create a correspondingly advantageous kit with an ophthalmic viscoelastic device.
[0015] This object is achieved according to the invention by an ophthalmic viscoelastic device according to claim 1 and by a kit according to claim 9 for use in eye surgery. Advantageous embodiments with expedient modifications of the invention are specified in the subclaims, wherein advantageous modifications of each aspect of the invention are to be regarded as advantageous modifications of the respective other aspect of the invention.
[0016] A first aspect of the invention relates to an ophthalmic viscoelastic device (OVD) comprising at least one viscoelastic polymer. According to the invention, the viscoelastic polymer comprises at least two polymer chains, each having at least one coordination group, wherein at least two coordination groups can be reversibly coupled to one another via at least one binding additive. In other words, according to the invention, the viscoelastic polymer of the OVD consists of at least two polymer chains. Each of the at least two polymer chains has at least one coordination group. Each coordination group can in principle be arranged terminally or within the polymer chain, for example, in the central region.In principle, more than one coordination group can be provided per polymer chain, for example two, three, four or more, which can then each have the same or different configurations, with identically configured coordination groups per polymer chain being preferred. The coordination groups are designed to be coupled to one another by means of the binding additive, as a result of which the individual polymer chains are cross-linked and accordingly form a longer-chain polymer with a higher molecular weight. According to the invention, the coupling is reversible and can therefore be cleaved again by an appropriate physical and / or chemical stimulus, as a result of which the viscoelastic polymer can break down again into the polymer chains, each with a lower molecular weight. The coordination groups can in principle have the same or different configurations with regard to different polymer chains. Depending on the type of polymer chains used, the coordination groups can be...The coordination group(s) can be introduced into the respective polymer chain by derivatizing a base polymer chain. For other polymer chains, existing coordination group(s) can be used directly without further derivatization steps. In certain embodiments, the shorter-chain polymer chains can themselves also be viscoelastic and, after coupling, form a longer-chain polymer with different rheological properties that is still viscoelastic. In other embodiments, the shorter-chain polymer chains can not be viscoelastic in themselves, but can form the viscoelastic polymer after their coupling as described above. As a result, the rheological properties of the OVD can be adapted particularly precisely to the respective requirements of an eye operation and, if necessary, varied during the eye operation.For example, in one application, the OVD can already contain the binding additive or be mixed with it from the outset. In this form, the OVD can then be introduced into the patient's eye as a cohesive viscoelastic polymer with a correspondingly higher molecular weight, with the polymer chains already coupled via the binding additive. After use, the viscoelastic polymer can then be split back into the individual, shorter-chain polymer chains by cleaving the polymer chains previously coupled or cross-linked by the binding additive and the coordination groups. These then do not need to be removed from the eye at the end of the operation, as they are preferably small enough to be naturally removed from the eye through the trabecular meshwork or the pores of Schlemn's canal and biodegrade. In this way, a corresponding time saving can be achieved without the risk of a subsequent increase in intraocular pressure.In some embodiments and depending on the ingredients used in the OVD, the cleavage of the coupling mediated by the binding additive and the coordination groups can occur spontaneously under the conditions prevailing in the eye, but is preferably initiated by the addition of an appropriate cleaving agent, which enables a precisely controllable cleavage of the viscoelastic polymer into the shorter-chain polymer chains. In an alternative application, the OVD can initially be used with decoupled polymer chains and without the addition of the binding additive as a dispersive viscoelastic polymer with a correspondingly lower molecular weight. After use orTowards the end of the eye surgery, the shorter-chain polymer chains can then be coupled and cross-linked via their coordination groups by adding the binding additive, creating a higher-viscosity, cohesive polymer that can then be removed from the eye by a surgeon more quickly, easily, and reliably than would be possible with the shorter-chain, dispersive polymer chains. Particularly in the second embodiment, the binding additive can initially be stored separately from the polymer chains of the OVD and only added to the OVD when needed or brought into contact with the shorter-chain polymer chains and their coordination groups to effect the described coupling to the longer-chain polymer.
[0017] It has proven particularly advantageous for use as a dispersive OVD for at least one polymer chain to have an average molecular weight of at most 60 kDa, in particular of at most 50 kDa. Alternatively or additionally, advantageous handling can be achieved by providing the viscoelastic polymer and / or the polymer chains in a concentration between 10 mg / ml and 20 mg / ml, in particular approximately 15 mg / ml. In the context of the present disclosure, concentrations of the viscoelastic polymer and the polymer chains generally refer to the respective concentration in the OVD prior to introduction into the eye, unless otherwise stated.
[0018] In a further advantageous embodiment of the invention, the viscoelastic polymer has a zero shear viscosity of at least 10 Pas, in particular of at least 150 Pas, and / or of at most 5000 Pas at 25 °C (and an air pressure of 1 bar). Alternatively or additionally, the polymer chains have a zero shear viscosity of at most 1 Pas, in particular of at most 0.01 Pas, and preferably of at most 0.001 Pas at 25 °C. This allows the OVD to be optimally adjusted for all common applications in eye surgery. It is understood that the definition of standard conditions does not preclude the possibility that the OVD or its ingredients may also have the aforementioned properties at different temperatures and / or pressures.
[0019] Further advantages arise from the fact that at least one polymer chain comprises at least one formation block from the group consisting of hyaluronic acid, alginate, chitosan, methylcellulose, hydroxypropylmethylcellulose, chondroitin sulfate, collagen, and gelatin. Corresponding derivatives and salts of the aforementioned formation blocks, such as hyaluronates, alginates, chitosan salts, etc., are generally included. Within the context of the present disclosure, a formation block is understood to mean monomeric, oligomeric, or polymeric structural elements or polymer chains, which, in the case of coupled polymer chains, thus also form formation blocks of the viscoelastic polymer. Through the previously discussed cleavage of the coupling mediated by the binding additive and the coordination groups, the viscoelastic polymer can preferably be cleaved back into these original formation blocks or into polymer chains that in turn consist of these formation blocks.Furthermore, it can be provided that the viscoelastic polymer, apart from coordination groups and binding additive(s), consists exclusively of one of the aforementioned building blocks, for example, exclusively of hyaluronic acid or hyaluronate blocks. Conversely, it can also be provided that the viscoelastic polymer or the polymer chains consist of two or more different building blocks.
[0020] In a further advantageous embodiment of the invention, the binding additive comprises a molecule that can be coupled to the at least two coordination groups via non-covalent bonds, in particular via weak chemical bonds. In other words, the invention provides that a molecule is used as the binding additive that preferably couples the coordination groups of the polymer chains to one another via van der Waals bonds, dipole-dipole interactions, hydrogen bonds, or any combination of these weak chemical bonds. The omission of covalent bonds represents a particularly simple and flexible option for realizing reversible coupling or cross-linking of the individual polymer chains, since no chemically aggressive cleaving agents need to be used in the patient's eye to cleave the coupled polymer chains again.
[0021] In a further advantageous embodiment of the invention, it is provided that at least one coordination group is designed as a mono- or polydentate metal coordination group and the binding additive comprises at least one metal ion as an ionic crosslinker, in particular at least one monovalent or polyvalent cation from the group Li + , N / a + , K + , Cs + , Rb + , Mg 2+ , Ca 2+ , Ba 2+ , Sr 2+ , Mn 2+ , Zn 2+ , Cu 2+ / 3+ and Fe 3+. Preferably, the coordination groups of the polymer chains are each bidentate, tridentate, tetradentate, or pentadentate, which on the one hand allows the formation of stable metal-ligand complexes, while on the other hand the formed metal-ligand complex can nevertheless be cleaved again by adding a more highly dentate cleaving agent such as EDTA (hexadentate). The metal ion is preferably a physiologically acceptable cation, which can be used, for example, as a physiologically acceptable salt with correspondingly physiologically acceptable anions such as chloride, sulfate, and / or nitrate, or can be added to the OVD. In some embodiments, the cation may not be Ca 2+ -ion.
[0022] Further advantages arise from the fact that the binding additive concentration is between 10 mg / ml and 100 mg / ml, particularly approximately 50 mg / ml, based on the volume of the OVD. This allows sufficient cross-linking of the polymer chains to be achieved in most cases.
[0023] In a further advantageous embodiment of the invention, it is provided that a coupling between the coordination groups and the binding additive leads to a color change compared to a non-coupled state. In other words, the change between the coupling and decoupling states leads to a color change, whereby either both states can have a respective color or one of the two states can be colorless. As a result, the current status or status change of the OVD can be directly visually tracked and assessed by a user. Preferably, the OVD is in a colorless state during eye surgery. Coloration can, in particular, facilitate the removal of the OVD at the end of eye surgery. Alternatively or additionally, it is provided that the coupling between the coordination groups and the binding additive takes place within a maximum of 5 s, preferably within a maximum of 2 s, after contact.In this way, a correspondingly fast status change between the coupled and the decoupled state and thus between the different rheological properties of the OVD can be realized.
[0024] A second aspect of the invention relates to a kit for use in eye surgery, comprising an ophthalmic viscoelastic device according to the first aspect of the invention, as well as at least one binding additive by means of which the at least two coordination groups of the polymer chains can be reversibly coupled to one another, and / or at least one cleaving agent by means of which a coupling between the coordination groups and the binding additive can be removed in order to split the viscoelastic polymer into the polymer chains. In other words, the kit comprises an OVD according to the first aspect of the invention and a binding additive by means of which the polymer chains can be reversibly coupled or uncoupled via their coordination groups.can be cross-linked, and / or a cleaving agent by means of which, particularly in vivo, i.e. in the patient's eye, at least some of the coordination group-binding additive couplings, and preferably the majority or all of these couplings, are cleaved again, resulting in shorter-chain polymer or oligomer chains with correspondingly lower molecular weight and different rheological properties. These shorter-chain degradation products can then be easily washed out of the anterior chamber via natural processes without clogging the trabecular meshwork. The cleavage or decomposition of the OVD can be controlled particularly precisely by appropriately selecting the type and amount of cleaving agent as well as the time of its addition to the OVD. This mechanism can, of course, in principle also be used for in vitro methods.The viscoelastic polymer can also be referred to as a transitional viscoelastic, which can be left in the eye by the surgeon in comparatively significant quantities, where it is broken down by the breaking agent and transported away and eliminated through the body's natural processes without causing a dangerous increase in intraocular pressure. A further advantage is that the previously required, lengthy and complicated step of suctioning out the viscoelastic after eye surgery can be completely eliminated. The kit according to the invention can be used in various eye surgeries, particularly in eye surgeries where there is a risk of postoperatively increased intraocular pressure. This applies, for example, to operations on the anterior segment of the eye such as cataract surgery, corneal transplants and glaucoma surgery. The binding additive and / or the breaking agent can orcan generally be added before the OVD, together with the OVD and / or after the OVD or at the end of the eye surgery. The OVD and the binding additive and / or the cleaving agent are preferably present in one or more syringes so that they can be used immediately. A syringe can have two, three or more chambers that are fluidically separated at least until use in order to prevent mixing of the OVD and binding additive and / or OVD and cleaving agent and thus undesired coupling or decoupling of the polymer chains during storage of the kit. The OVD and the binding additive can optionally be administered together using preferably the same syringe or mixed in the syringe or in a mixing chamber of the syringe before administration.For this purpose, the chambers can be separated, for example, by at least one partition wall, which is pierced during administration to establish a fluidic connection and mix the OVD with the binding additive and / or the cleaving agent. The OVD or the kit can in principle contain additional ingredients such as pH buffer systems or the like. Further features and their advantages can be found in the descriptions of the first aspect of the invention, with advantageous embodiments of each aspect of the invention being considered advantageous embodiments of the other aspect of the invention.
[0025] In an advantageous embodiment of the invention, the cleaving agent comprises a preferably multidentate complexing agent, in particular EDTA (ethylenediaminetetraacetic acid). This allows particularly reliable cleaving of ionically cross-linked polymer chains, since EDTA, as a hexadentate chelating agent, preferably has a higher binding affinity to the metal ion of the metal-ligand complex than the coupling groups of the polymer chains. Preferably, the cleaving agent forms the complex at least substantially only with the metal ion used for cross-linking. Preferably, the cleaving agent does not form, or at least does not form, stable complexes with Ca. 2+Ions, as these are important for many biological functions in the anterior chamber. Alternatively or additionally, the kit may include a dye to indicate the coupled or uncoupled state of the OVD or to facilitate a surgeon's removal of the OVD from the eye.
[0026] Further features of the invention emerge from the claims, the figures and the description of the figures. The features and combinations of features mentioned above in the description, as well as the features and combinations of features mentioned below in the description of the figures and / or shown alone in the figures can be used not only in the respective combination specified, but also in other combinations without departing from the scope of the invention. Thus, embodiments are to be regarded as encompassed and disclosed by the invention that are not explicitly shown and explained in the figures, but which emerge and can be produced by separate combinations of features from the explained embodiments. Embodiments and combinations of features are also to be regarded as disclosed that therefore do not have all the features of an originally formulated independent claim.Furthermore, embodiments and combinations of features are to be considered disclosed, in particular by the embodiments presented above, which go beyond or deviate from the combinations of features presented in the claims. This shows:
[0027] Fig. 1 is a schematic representation of a viscoelastic polymer of an ophthalmic viscoelastic device (OVD) according to an embodiment of the invention;
[0028] Fig. 2 is a schematic representation of a viscoelastic polymer of the ophthalmic viscoelastic device according to the invention, which is cleaved by means of a cleaving agent;
[0029] Fig. 3 is a schematic diagram of a relationship between a concentration of a binding additive in the OVD and a resulting zero shear viscosity of the OVD;
[0030] Fig. 4 is a schematic diagram of a time course of the zero shear viscosity of the OVD according to the invention during different phases of an eye surgery; and Fig. 5 is a schematic representation of a disaccharide repeat unit of hyaluronic acid.
[0031] Preferred embodiment of the invention
[0032] Fig. 1 shows a schematic representation of a viscoelastic polymer 10 of an ophthalmic viscoelastic device (OVD) according to an embodiment of the invention. The viscoelastic polymer 10 comprises a plurality of shorter-chain polymer chains 12, each having one or more coordination groups 14. In the state shown in Fig. 1, the polymer chains 12 are reversibly coupled to one another via their respective coordination groups 14 with the aid of a binding additive 16, which can also be referred to as a stabilizer molecule. For example, the coordination groups 14 can be formed as mono-, bi-, tridentate, or tetradentate metal coordination groups. Metal ions are then used as the binding additive 16, which, together with the metal coordination groups 14, act as ionic crosslinkers. Suitable metal ions are generally monovalent or polyvalent cations from the group Li + , N / a + , K + , Cs +, Rb + , Mg 2+ , Ca 2+ , Ba 2+ , Sr 2+ , Mn 2+ , Zn 2+ , Cu 2+ / 3+ and Fe 3+ , whereby the mentioned cations can in principle be used individually or in any combination.
[0033] As an alternative to metal ions as binding additives 16, molecules can also be used that interact with the corresponding coordination groups 14 of the polymer chains 12 via weak chemical interactions, i.e., in particular, without the formation of covalent bonds, thus causing reversible coupling. If necessary, the pH of the OVD can be adjusted to a required value or within a desired range. The OVD can also contain a pH buffer system to reliably maintain a specific pH range.
[0034] Fig. 2 shows a schematic representation of the viscoelastic polymer 10 of the ophthalmic viscoelastic device (OVD) according to the invention, which is cleaved by means of a cleavage agent 18. In the present example, EDTA (ethylenediaminetetraacetic acid) is used as the cleavage agent 18, which, as a hexadentate complexing agent, forms more stable complexes with the metal ions used as binding additives 16 than the metal coordination groups 14 of the polymer chains 12. Alternatively, other complexing agents can also be used. Preferred complexing agents are those containing Ca 2+ If possible, do not bind or at least not bind stably, since gallons fulfill important biological functions in the anterior chamber.
[0035] The cleaving agent 18 cleaves the viscoelastic polymer 10 and releases the shorter-chain polymer chains 12, changing the rheological properties of the OVD accordingly. Coupling and decoupling rates (phase change rates) of less than 5 seconds, preferably less than 2 seconds or less than 1 second, are desired so that the OVD changes its rheological properties as quickly as possible. Depending on the binding additive 16, the kinetics between the two viscosity states can lead to a preference for the highly viscous phase (e.g., solidification, gelation, etc.).
[0036] Fig. 3 shows a schematic diagram of a relationship between a concentration c of a binding additive 16 in the OVD and a resulting zero-shear viscosity V of the OVD. The time concentration c is plotted on the abscissa, while the zero-shear viscosity V is plotted on the ordinate. It can be seen that the zero-shear viscosity V can be adjusted with increasing concentration of the binding additive 16, from a range IIIa of low viscosity, through a range IHb of medium viscosity, to a range IIIle of high viscosity. Thus, the degree of crosslinking of the viscoelastic polymer 10 and thus the viscosity of the OVD can be precisely adjusted to a desired value by varying the concentration of the binding additive 16.
[0037] Fig. 4 shows a schematic diagram of the time course of the zero shear viscosity V of the OVD according to the invention during different phases A, B, and C of an eye operation. The time t is plotted on the abscissa, while the zero shear viscosity V is plotted on the ordinate. Phase A denotes the state before the operation, while the OVD is, for example, in a syringe. It can be seen that the OVD in this example is designed as a highly viscous, cohesive OVD. Accordingly, the OVD is mixed with the binding additive 16 from the outset and is highly cross-linked. During the eye operation (phase B), the OVD is introduced into the patient's eye, for example, to fill the anterior chamber. At the end of the operation (phase C), the cleaving agent 18 is added to the OVD, which decouples the individual polymer chains 12 from one another or cleaves the reversible crosslinks.This decreases the zero-shear viscosity V until most or all couplings are eliminated and the viscoelastic polymer 10 has decomposed into its shorter-chain polymer chains 12. The polymer chains 12 no longer need to be removed from the eye by the surgeon, as they are transported out of the eye via natural pathways (trabecular meshwork, Schlemm's canals) and degraded by the body. The aqueous humor can also transport the cleavage agent 18 and the binding additive 16 away.
[0038] Fig. 5 shows a schematic representation of a disaccharide repeat unit of hyaluronic acid. Such a D-glucuronic acid-N-acetyl-D-glucosamine disaccharide has a size of approximately 1 nm. Arrows Va–Vg mark various reactive functional groups and potential reaction centers for derivatization of hyaluronic acid (HA). Va denotes a carboxyl group, Vb a primary hydroxyl group, Vc the reductive end group of HA, Vd an N-acetyl group, and Ve, Vf, and Vg secondary hydroxyl groups. These functional groups can be used to attach coordination groups, for example, mono-, bidentate, or polydentate metal coordination groups, to the HA backbone in various ways.
[0039] The OVD according to the invention can, in principle, be configured and used for a variety of applications and workflows. This is illustrated by the following example of an eye surgery on a human eye, which is known to have an anterior chamber, a posterior chamber, and a capsular bag in the posterior chamber.
[0040] In step 1, a desired amount of the binding additive 16, which acts as a thickener, is added to the OVD according to the invention in order to crosslink the polymer chains 12 to form the viscoelastic polymer 10 with an increased viscosity. In a fundamentally optional step 2, the desired amount of binding additive 16 is added to a second OVD according to the invention if two OVDs with different rheological properties are desired or required. In step 3, the eye is surgically opened. In step 4, the anterior chamber is filled with an OVD according to the invention. In step 5, a capsulotomy is then performed. Step 6 then involves the removal of the cataractous tissue. In step 7, the capsular bag is filled with the same OVD or another OVD according to the invention. In step 8, an intraocular lens (IOL) is implanted into the capsular bag. In step 9.At the end of the operation, the cleaving agent 18 is then introduced into the eye to decompose the viscoelastic polymer 10 of the OVD into the shorter-chain polymer chains 12. In a fundamentally optional step 10, a portion of the OVD is removed from the eye. It depends on the surgeon's assessment and the clinical situation whether the OVD should be partially or predominantly removed, or whether step 10 can be omitted.
[0041] As the polymer chains 12 of the OVD, a polysaccharide can be used in a concentration and with a molecular weight that preferably has a low viscosity below 1 Pas. For example, hyaluronic acid with a molecular weight of 50 kDa or less can be used in a concentration of about 15 mg / ml.
[0042] The binding additive 16 can be a concentrated solution of divalent or trivalent metal ions (with corresponding counterions) that form a metal-ligand complex with the polymer chains 12 or their coordination groups 14. For example, when using hyaluronic acid, calcium chloride or magnesium chloride can be added at a concentration of 50 mg / ml to effect reversible crosslinking to the highly viscous polymer 10. The amount to be added depends on the final viscosity desired by the surgeon, which can, for example, be 150 Pas or more.
[0043] A substance is used as the cleavage agent 18 that captures or complexes the metal ions without increasing the viscosity. If the metal ions are Ca 2+ - and / or Mg 2+ - ions is used, EDTA is particularly suitable for this purpose.
[0044] In a preferred embodiment, the ions used as binding additives 16 are multivalent and physiologically acceptable (e.g., Mn 2+ , Cu 2+ , Fe 3+ etc.) and the cleavage agent 18 binds these ions as specifically as possible and preferably no physiologically relevant ions such as Mg 2+ or Ca 2+ In another preferred embodiment, the OVD or polymer chains 12, the binding additive 16, and the cleaving agent 18 are each supplied in separate packages or compartments ready for use in the surgical environment.
[0045] In another preferred embodiment, the polymer chains 12 and the binding additive 16 are already premixed in the OVD and, in further embodiments, can be present in one variant or in two or more variants with different rheological properties. These ready-to-use OVDs are preferably supplied together with the cleaving agent 18, which can then be added at the desired time.
[0046] In an alternative workflow, step 1 involves surgically opening the patient's eye. In step 2, the anterior chamber of the eye is filled with an OVD according to the invention, which is designed as a disperse OVD with a low degree of cross-linking or with completely uncross-linked, viscoelastic polymer chains 12. In step 3, a capsulotomy is performed. In step 4, the cataractous tissue is removed. In step 5, the capsular bag is filled with the same OVD or with another OVD according to the invention with different rheological properties. In step 6, an intraocular lens is implanted into the capsular bag. In step 7, the binding additive 16 is added to the OVD in the desired amount. This can be done, for example, with a syringe or by switching the ophthalmic irrigation solution (OIS) to an OIS containing the binding additive 16.The binding additive 16 crosslinks the polymer chains 12 in the manner described to form the higher molecular weight viscoelastic polymer 10, whereby the OVD becomes more cohesive and can ultimately be removed from the eye in step 8. more easily than in its originally dispersive state.
[0047] The OVD can, in principle, contain any commonly used viscoelastic polymer 10 and is preferably formed from blocks of hyaluronic acid or hyaluronate (HA), chondroitin sulfate (CS), hydroxypropylmethylcellulose (HPMC), or mixtures thereof. Optionally, the corresponding polymer chains 12 can be derivatized to introduce desired coordination groups 14. The binding additive 16 can be a chelating agent, which can be in the form of an aqueous solution and, for example, can contain divalent or trivalent metal ions such as Ca. 2+ , Mg 2+ or Fe 3+In a preferred embodiment, the binding additive 16 is added with a syringe. In another preferred embodiment, the divalent or trivalent metal ions are contained in the ophthalmic rinse solution (OIS).
[0048] The user has two bags of OIS, the first of which is conventional OIS and the second of which additionally contains the divalent or trivalent metal ions. After implanting the IOL, the surgeon switches from the first OIS to the second OIS. In another preferred embodiment, metal ions are used, which, together with the OVD, form a colored gel to assist removal. Optionally, a dye can also be added to the cleaving agent 18.
[0049] The parameter values given in the documents for defining process and measurement conditions for the characterization of specific properties of the
[0050] Subject matter of the invention are to be regarded as being encompassed by the scope of the invention even in the case of deviations - for example due to measurement errors, system errors, DIN tolerances and the like.
[0051] List of reference symbols
[0052] 10 viscoelastic polymer
[0053] 12 Polymer chain 14 Coordination group
[0054] 16 Binding additive
[0055] 18 splitting agents
[0056] Illa low viscosity lllb medium viscosity Ille high viscosity
[0057] V Zero shear viscosity c Concentration t Time
[0058] A, B, C Phase Va-Vg functional groups of hyaluronic acid
Claims
Patent claims 1. An ophthalmic viscoelastic device comprising at least one viscoelastic polymer (10), characterized in that the viscoelastic polymer (10) comprises at least two polymer chains (12) each having at least one coordination group, wherein at least two coordination groups (14) are reversibly coupled to one another via at least one binding additive (16).
2. Ophthalmic viscoelastic device according to claim 1, characterized in that at least one polymer chain has an average molecular weight of at most 60 kDa, in particular of at most 50 kDa and / or that the viscoelastic polymer (10) and / or the polymer chains (12) are present in a concentration between 10 mg / ml and 20 mg / ml, in particular about 15 mg / ml.
3. Ophthalmic viscoelastic device according to claim 1 or 2, characterized in that the viscoelastic polymer (10) has a zero shear viscosity of at least 10 Pas, in particular of at least 150 Pas, and / or of at most 5000 Pas at 25 °C and / or that the polymer chains (12) have a zero shear viscosity of at most 1 Pas, in particular of at most 0.01 Pas and preferably of at most 0.001 Pas, at 25 °C.
4. Ophthalmic viscoelastic device according to one of claims 1 to 3, characterized in that at least one polymer chain comprises at least one forming block from the group consisting of hyaluronic acid, alginate, chitosan, methylcellulose, hydroxypropylmethylcellulose, chondroitin sulfate, collagen and gelatin.
5. Ophthalmic viscoelastic device according to one of claims 1 to 4, characterized in that the binding additive (16) comprises a molecule which can be coupled to the at least two coordination groups (14) via non-covalent bonds, in particular via weak chemical bonds.
6. Ophthalmic viscoelastic device according to one of claims 1 to 5, characterized in that at least one coordination group is designed as a mono- or polydentate metal coordination group and the binding additive (16) comprises at least one metal ion as an ionic crosslinker, in particular at least one monovalent or polyvalent cation from the group Li + , N / a + , K + , Cs + , Rb + , Mg 2+ , Ca 2+ , Ba 2+ , Sr 2+ , Mn 2+ , Zn 2+ , Cu 2+ / 3+ and Fe 3+ .
7. Ophthalmic viscoelastic device according to one of claims 1 to 6, characterized in that a concentration of the binding additive (16) is between 10 mg / ml and 100 mg / ml, in particular about 50 mg / ml.
8. Ophthalmic viscoelastic device according to one of claims 1 to 7, characterized in that a coupling between the coordination groups (14) and the binding additive (16) leads to a color change compared to a non-coupled state and / or that the coupling between the coordination groups (14) and the binding additive (16) takes place after contacting within a maximum of 200 ms, preferably within a maximum of 100 ms.
9. Kit for use in eye surgery, comprising an ophthalmic viscoelastic device according to one of claims 1 to 8, and at least one binding additive (16) by means of which the at least two coordination groups (14) of the polymer chains (12) can be reversibly coupled to one another, and / or at least one cleaving agent (18) by means of which a coupling between the coordination groups (14) and the binding additive (16) can be removed in order to cleave the viscoelastic polymer (10) into the polymer chains (12).
0. Kit according to claim 9, characterized in that the splitting agent (18) comprises a preferably multidentate complexing agent, in particular EDTA, and / or a dye.
Citation Information
Patent Citations
Carrageenan viscoelastics for ocular surgery
US20040019010A1
Methods for reducing postoperative intraocular pressure
US6745776B2
